Login / Signup

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.

Zifu YaoAnqi LinYonglin YiWeitao ShenJian ZhangPeng Luo
Published in: Drug design, development and therapy (2022)
THSD7B can be considered a reliable biomarker that effectively facilitates the prediction of poor survival in SCLC platinum-treated patients.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • single cell
  • cell therapy
  • stem cells
  • patient reported outcomes
  • free survival
  • patient reported